Overview

Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas

Status:
Unknown status

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

A randomized multi-center phase II trial of nab-paclitaxel in combination with gemcitabine verus S1 with gemcitabine as first-Line treatment for locally advanced or metastatic pancreatic cancer

Phase:

Phase 2

Details

Lead Sponsor:

Wuhan Union Hospital, China

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel
Pancrelipase